SCHEDULE: ImmunityBio: Major Stakeholder Disclosures Revealed

An amended Schedule 13D filing for ImmunityBio, Inc. details substantial beneficial ownership by Patrick Soon-Shiong and affiliated entities, collectively holding a significant portion of the company's common stock.

Summary

• This filing is an amendment to a Schedule 13D, reporting changes in beneficial ownership of ImmunityBio, Inc. common stock.
• Patrick Soon-Shiong, along with several affiliated entities including Cambridge Equities, LP, MP 13 Ventures, LLC, NantWorks, LLC, Nant Capital, LLC, California Capital Equity, LLC, and NantBio, Inc., NantMobile, LLC, NCSC, and the Chan Soon-Shiong Family Foundation, collectively hold a significant stake.
• As of July 31, 2026, Patrick Soon-Shiong may be deemed to beneficially own 745,518,285 shares, representing approximately 64.8% of the class of securities.
• This percentage is calculated based on the total shares outstanding (1,059,836,273) plus certain shares issuable upon option exercise and note conversion.
• The filing details the specific shareholdings and voting/dispositive power attributed to each reporting person and their respective entities.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, primarily due to the significant beneficial ownership reported by Patrick Soon-Shiong and associated entities, indicating concentrated control rather than a positive operational update.

Positives

• The filing provides clarity on the beneficial ownership structure and the significant stake held by key individuals and entities associated with the company.
• The detailed breakdown of shareholdings across various entities offers transparency regarding control and influence.

Negatives

• The high percentage of beneficial ownership by a single individual and associated entities could indicate concentrated control, potentially limiting independent decision-making or strategic flexibility.
• The filing does not provide any new operational, financial, or strategic updates for ImmunityBio, Inc., focusing solely on ownership disclosures.

Risks

• Concentration of voting power in a single individual or closely affiliated group could pose governance risks if not managed effectively.
• The significant stake held by Dr. Patrick Soon-Shiong and his entities means that any strategic decisions or changes in his investment strategy could have a substantial impact on the company's stock price and direction.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance. It is solely an update on beneficial ownership.

Management Comments

• Dr. Soon-Shiong may be deemed to beneficially own, and share voting power and investment power over, all shares of the Issuer's Common Stock beneficially owned by Cambridge, California Capital, NantWorks, NantBio, NantMobile, NCSC, Nant Capital, and the Chan Soon-Shiong Family Foundation.
• Dr. Soon-Shiong disclaims beneficial ownership of the shares of the Issuer's Common Stock beneficially owned by Cambridge, California Capital, NantWorks, NantBio, NantMobile, NCSC, Nant Capital, and the Chan Soon-Shiong Family Foundation, except to the extent of his pecuniary interest.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are common in the biotechnology and pharmaceutical sectors, often reflecting significant investments by venture capital firms, private equity, or key individuals during development stages or periods of strategic change. The high concentration of ownership here is notable within this context.

Corporate Governance

Related Party Transactions

• The filing details significant shareholdings and shared voting/dispositive power among Patrick Soon-Shiong and various entities he controls or is associated with, including Cambridge Equities, LP, MP 13 Ventures, LLC, NantWorks, LLC, Nant Capital, LLC, California Capital Equity, LLC, NantBio, Inc., NantMobile, LLC, NCSC, and the Chan Soon-Shiong Family Foundation. This indicates a complex web of related parties with substantial interests in ImmunityBio, Inc.

Stakeholder Impact

• Shareholders: The concentrated ownership by Patrick Soon-Shiong and associated entities could influence corporate strategy and decision-making, potentially impacting shareholder value. Minority shareholders may have less influence on corporate governance.
• Management: Management's actions and strategic decisions may be heavily influenced by the significant stake and potential control exercised by Dr. Soon-Shiong and his affiliated entities.

Key Dates

Keywords

Schedule 13D, Beneficial Ownership, Patrick Soon-Shiong, ImmunityBio, Cambridge Equities, NantWorks, Nant Capital, Shareholder